A federal advisory panel voted Thursday to relax rules on seven peptides, including BPC-157 and TB-500. The vote was slim. It is not binding. The FDA has given no word on whether it will adopt the suggestion. The move came after weeks of open hearings. Wellness backers pushed hard for wider access. RFK Jr. was among them. Critics say these compounds have little hard evidence of safety or help for most uses. The call could reshape how the agency handles a part of the wellness market that is surging ahead. Patient groups are waiting to see if the regulator moves in step. A spokesperson for the regulator offered no fixed date for a next step. Backers argue the change would widen access to products users find useful. Skeptics warn that looser rules could invite misuse across a quickly growing market. The Thursday vote only plants the seed for a shift, and the final call rests with the federal regulator.